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Oncoprotein-targeted drug therapies offer an alternative to cytotoxic drugs for
the treatment of cancer [11, 20, 23, 29]. However, resistance to targeted therapies
poses a major clinical challenge to their broader use. In addition to acquired re-
sistance, where cancer cells acquire mutations under the selective pressure of
drug treatment, recent studies have implicated cells of the tumor microenvi-
ronment in mediating innate resistance to targeted therapies [41, 48]. Stromal
cells can confer resistance by secreting cytokines that activate alternative sig-
naling pathways in cancer cells so that they can continue to grow and prolifer-
ate despite exposure to drug. In this dissertation, I use a supervised machine
learning approach to model tumor-stromal interactions that mediate drug resis-
tance from a published data set where stromal-mediated drug resistance is mea-
sured from co-culture experiments. My model, a multi-task bilinear regression,
called multi-task affinity regression predicts how cytokines secreted by stromal
cells interact with pathways in cancer cells to mediate innate drug resistance
to molecularly targeted therapies. I computationally identified and experimen-
tally validated HGF as a secreted factor that mediates resistance to the EGFR
inhibitors in lung cancer cell lines. I also compared my model to an alternative
method in the classification setting called multi-task pairwise support vector
machine (SVM). The method was also used to model binding of DNA/RNA
to transcription factors (TFs)/RNA binding proteins (RBPs) in protein binding
microarray and RNAcompete experiments [40]. We hope this work will pro-
vide new insights into how stromal cells promote drug resistance and how we
might treat cancer with combination therapies that target the tumor microenvi-
ronment. More generally this dissertation can serve as a point of reference for
scientists looking to use supervised machine learning methods to model biolog-
ical interactions where a high-throughput affinity readout is available.
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CHAPTER 1
INTRODUCTION
1.1 Background
Targeted cancer therapies, which include small molecules and blocking anti-
bodies that inhibit a specific molecular target within the tumor cell, have seen
marked success in clinical trials in the past two decades [11, 20, 23, 29]. Tar-
geted therapies represent a significant advance in personalized medicine as
they are used specifically on patients whose tumors harbor the genetic muta-
tions that give rise to targeted oncogenic proteins. As opposed to chemother-
apeutic drugs, which kill rapidly dividing cells indiscriminantly, targeted ther-
apies offer a promising treatment option that effects only cancer cells express-
ing specific molecules. The success of targeted therapies and their advantages
over chemotherapy points to target therapies as a important alternative treat-
ment against cancer. However, the emergence of drug resistance in the 2000s
in clinical trials posed a serious challenge to the success of these treatments
[1, 7, 22, 39]. In these clinical trials, a large percentage of the treatment cohort
were either non-responders or responders who would fail to respond after a
period of time. Drug resistance poses a major problem for targeted therapies,
and it is important to study mechanisms of drug resistance to develop treat-
ment strategies that will overcome these challenges. This thesis studies tumor
microenvironment-mediated innate drug resistance by modeling molecular in-
teractions between the tumor and stromal cells using supervised machine learn-
ing methods. This analysis provides new insights into the mechanisms that me-
diate drug resistance and may eventually suggest treatment strategies such as
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combination therapies that can target both the tumor and microenvironment to
overcome drug resistance.
Research on targeted therapies for cancer treatment can be traced back to as
early as 1960 when researchers found a chromosomal abnormality leading to the
expression of mutant kinase BCR-ABL on chromosome 22 in chronic granulo-
cytic leukemia [29]. They named the chromosomal abnormality the Philadel-
phia Chromosome. Later imatinib (Gleevec) one of the first targeted cancer
therapies was developed as an inhibitor of mutant kinase BCR-ABL. In the late
1990s and early 2000s, the FDA began to approve the first molecularly targeted
cancer drugs. In 1997, the FDA approved rituximab (Rituxan) to treat patients
with non-Hodgkin lymphoma [11]. In 1998, the FDA approved trastuzumab
(Herceptin), a monoclonal antibody that was added to chemotherapy to treat
women with advanced breast cancer that over-expressed HER2 [23]. In 2001,
the FDA approved imatinib (Gleevec) to treat chronic myelogenous leukemia
(CML) [20]. These targeted therapies allowed specific cohorts of patients to
avoid the negative effects of cytotoxicity from chemotherapy.
Despite the initial success of targeted therapies, drug resistance soon
emerged as a serious a challenge. There are two types of drug resistance: ac-
quired resistance, which develops during the course of treatment in response to
therapy, and innate resistance, which is inherent in the body and present even
before treatment begins [19]. For many targeted therapies, some patients do
not respond (innate resistance) or some patients fail to continue to respond af-
ter a period of time despite a significant initial response to therapy (acquired
resistance). For imatinib (Gleevec), in the treatment of chronic myelogenous
leukemia (CML), 33% of patients will have an inferior response, either fail-
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ing to respond to primary therapy or demonstrating relapse after an initial re-
sponse due to acquired drug resistance [7]. Trastuzumab (Herceptin) is an ef-
fective targeted drug in the treatment of HER2-positive breast cancer. However,
20% of early stage breast cancer patients and approximately 70% of patients
with metastatic disease are resistant to treatment [28]. More recently imatinib
(Gleevec) was also shown to block c-KIT tyrosine kinase in patients with KIT
mutant melanoma [22]. Despite the initial response to imatinib treatment, drug
resistance emerged for most cases after a short period of time eventually lead-
ing to relapse. Vemurafenib, a drug that targets BRAFV600E mutations, showed
more than 50% response rates in patients carrying the BRAF mutation. Despite
the high initial rate of response to therapy, a majority of the patients develop
resistance to vemurafenib after approximately six months of treatment [39, 33].
Drug resistance poses a challenge to the success of targeted therapies, and it
is important to study mechanisms of drug resistance in order to improve the
duration of response.
Cancers develop due to the accumulation of genetic and epigenetic alter-
ations that occur in initially normal cells. At same time, cancer cells develop
within a host microenvironment that is composed of a heterogeneous popula-
tion of stromal cells (fibroblasts, endothelial cells, adipocytes, immune cells and
bone marrow-derived stem cells), stromal cell secreted factors, and the extra-
cellular matrix. The host microenvironment has long been known to contribute
to tumor initiation, progression and metastasis [26]. Recently researchers have
proposed that the tumor microenvironment may also play a key role in modu-
lating cancer drug efficacy. In 2012, Todd Golub’s group at the Broad Institute
[41] and Jeffrey Settleman’s group at genentech [48] separately and concurrently
showed that stromal cells from the tumor microenvironment confer drug resis-
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tance through secreted factors. Targeted therapies were especially susceptible to
stromal mediated drug resistance. It was shown that stromal cells of the tumor
microenvironment could induce resistance in cancer cells by releasing soluble
factors called cytokines that elicit drug resistance in tumor cells.
In my thesis research, I modeled tumor-stromal interactions that mediate
drug resistance against anti-cancer targeted therapies. I used a multi-task bi-
linear regression method called multi-task affinity regression to model tumor-
stromal interactions that mediate drug resistance, jointly training across co-
cultures treated with different drugs of the same class. In my model, cytokines
of the stromal cells are thought to signal to the tumor cells reactivating onco-
genic signaling pathways in the tumor cells, leading to drug resistance. Through
statistical analysis of the affinity regression models, I identified cell-cell signal-
ing and cancer pathways involved in stromal-mediated drug resistance. Even-
tually, these approaches may lead to effective cancer treatment strategies such
as combination drug therapies that target both the tumor and the microenviron-
ment to counteract drug resistance.
Affinity regression is a bilinear regression where the observed data can be
modeled as interactions between two kinds of inputs [40]. The algorithm learns
a weighting on all such interactions that best explains the affinity of one input
for the other given the observed data. Affinity regression is closely related to
Partial Least Squares regression, developed by Herman Wold in 1966 [18], and
to Canonical Correlation Analysis, developed by Harold Hotelling in 1936 [17].
Bilinear regression was described by Ruben Gabriel Kramer in 1995 [32]. Our
bilinear regression method called affinity regression was developed by Raphael
Pelossof in 2010. It involves singular value decomposition (SVD) compressions
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of one of both inputs and regressing on the matrix of pairwise similarities of the
output response variables. Here we formulate a multi-task version of this bi-
linear regression to analyze biological interactions of co-cultures that have been
treated with multiple drug dosages. Our formulation is a bilinear regression
without the SVD compressions and using the original output matrix rather than
the kernelized version. We anticipate that our approach can be naturally ap-
plied to predict many other kinds of biological interactions where there is a
high-throughput affinity read-out.
1.2 Summary outline
This thesis is divided into three chapters that cover the key contributions of
my graduate work. Chapter 2 details the preliminary statistical data analysis I
performed on the tumor-stromal co-culture drug screen data set obtained from
Straussman et al. [41]. It includes the initial analyses of the drug resistance ob-
served in the co-cultures and a correlation analysis of the cytokines responsible
for mediating drug resistance in different subtypes of cancer treated with dif-
ferent anti-cancer therapies. Chapter 3 details the work I did to model tumor-
stromal interactions that mediate innate drug resistance to anti-cancer therapies
using multi-task affinity regression. I then explore an alternative method for
modeling the pairwise molecular interactions between tumor cells and stromal
cells using multi-task pairwise support vector machine (SVM) in a classifica-
tion framework and compare the performance of this alternative method with
multi-task affinity regression. Finally, chapter 4 describe another application of
affinity regression to Protein Binding Microarray (PBM) and RNAcompete ex-
periments. In chapter 4, I detail the contributions I made to the original affinity
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regression paper, using affinity regression to model the interactions between
the k-mer features of DNA/RNA probes and the K-mer amino acid features of
transcription factors/RNA binding proteins that predict the binding affinities
in Protein Binding Microarray (PBM) and RNAcompete experiments.
1.2.1 Statistical data analysis of tumor-stromal co-culture drug
screen
I performed a statistical analysis of the co-culture data set from Straussman
et al. [41] to establish feasibility of using affinity regression to model tumor-
stromal interactions mediating resistance against anti-cancer therapies. In these
co-culture experiments, co-culturing with stromal cells rescues cancer cells from
drug-mediated killing. To determine which drugs are potential candidates for
our study on innate drug resistance, I calculated a mean rescue score of the
co-cultures treated with different drug dosages to determine which drug and
dosage combination gives the best rescue of cancer cell lines by stromal cell
lines. I looked at cancer proliferation in the PLX4720 treated co-cultures to get
an idea of what drug resistance looks like in a positive and negative control
cases– in melanoma where drug resistance is known to occur and in colorectal
cancer where there is no drug resistance [1]. I looked at the relative proliferation
of the cancer cells with stroma against the proliferation of cancer cells without
stroma in melanoma and colorectal cell lines treated with different dosages of
PLX4720.
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Correlation analyses of the tumor-stromal co-culture drug screen
To identify of the cytokines correlated with strong drug resistance in a co-culture
system, melanoma cell lines with BRAF V600E mutations treated with PLX4720,
I repeated the statistical analysis performed by Straussman et al. [41], corre-
lating the average rescue scores of melanoma cell lines treated with PLX4720
with individual cytokine expression levels secreted by the stromal cell lines. I
confirmed that HGF is the cytokine most strongly correlated with resistance to
PLX4720 in melanoma cell lines (Fig. 2.5,2.6)). To see if there are cytokines
other than HGF that contribute to rescue in melanoma cell lines treated with
PLX4720, I performed another analysis, correlating the individual rescue scores
of the melanoma cell lines treated with PLX4720 with the cytokine expression
levels secreted by the stromal cell lines (Fig. 2.7, 2.8, 2.9, 2.10). I found evi-
dence that there may be other cytokines mediating resistance in melanoma cell
lines treated with PLX4720. Finally I performed a correlation analysis across co-
cultures treated with 15 different anti-cancer drugs. I calculated the correlation
of the secretion level of the cytokines and the rescue scores for cancer cell lines
and calculated an average correlation score for each subtype of cancer. I found
cytokines for each cancer type and each drug dosage that were highly correlated
with drug resistance.
1.2.2 Modeling tumor-stromal interactions that mediate innate
resistance to cancer therapies
Both innate and acquired resistance to molecularly targeted therapies represent
major challenges to cancer treatment. The importance of the tumor microen-
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vironment in cancer initiation and progression is well established [26], but we
are only beginning to understand the contributions of the microenvironment to
therapeutic response and innate drug resistance. To study this issue computa-
tionally, I used affinity regression to model the effect of stromal cells on cancer
cell drug sensitivity using a large published stromal-cancer co-culture data set
consisting of 45 cancer cell lines, 23 stromal cells lines, and 35 drugs [30]. I rep-
resented each stromal cell by a feature vector of expression levels of secreted cy-
tokines, measured by cytokine array in monoculture. I represented each cancer
cell by pathway scores derived from curated signaling pathway databases, giv-
ing a view of the cellular circuitry that could receive and transduce signals from
stromal cells. For each drug, the algorithm trained a regularized bilinear regres-
sion model that predicted the stromal rescue score for a cancer cell line from
the pair of stromal and cancer feature vectors. By analysis of the trained model,
I identified cytokines secreted by the stromal cell lines that may interact with
signaling pathways in the cancer cells to mediate rescue. I found that affinity
regression outperformed nearest neighbor approaches for the task of predicting
rescue scores in cross-validation experiments. Further, for the BRAF inhibitor
PLX4720, I confirmed that HGF is the cytokine most predictive of increased
cancer cell proliferation in co-culture, and HGF participates in re-activating c-
MET and PI3K/AKT signaling, consistent with published experimental reports
[48]. Furthermore I found that HGF plays a similar role in afatinib and erlotinib
treated NSCLC cell lines, while this interaction is not seen in NSCLC cell lines
treated with the general cytotoxic drug docetaxel. The model of tumor-stromal
interactions may lead to new insights into the role of stromal cells in promot-
ing drug resistance and ultimately into how to treat cancer with combination
therapies that target both the tumor and the microenvironment.
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I compare multi-task affinity regression to an alternative method multi-task
pairwise SVM. I describe a model that can be seen as the alternative to the
multi-task affinity regression that uses classification rather than regression for
modeling biological interaction data. I model the pairwise molecular interac-
tions between the stromal cells and the tumor cells to explain innate drug re-
sistance observed in the tumor-stromal co-culture drug screen using a multi-
task pairwise SVM. I compare the performance of the two methods using 10-
fold cross-validation trained on the tumor-stromal co-culture drug screen data
treated with 15 anti-cancer therapies.
1.2.3 Application of affinity regression to PBM and RNAcom-
pete data and comparison to multi-task pairwise SVM
In this chapter, I detail the contributions I made to the original affinity regression
paper in 2015 [40]. There, affinity regression was used to model protein bind-
ing microarray (PBM) or RNAcompete experiments to learn family-level bind-
ing models for transcription factors (TFs) and RNA binding proteins (RBPs).
There, we learned an interaction model between k-mer features of the nucleic
acids and the K-mer features of the proteins. In this project, I prepared the K-
mer feature matrices of the two inputs and the matrix of the binding affinities
for the RNA binding protein analysis. I generated motifs for the affinity re-
gression models for the Z-score affinity regression model for Z-scores obtained
from PBM and RNAcompete experiments using the PWM-Align-Z algorithm. I
plotted an example of the predicted and experimental Z-scores from the Z-score
affinity regression model. I visualized the motifs for the RNA binding proteins
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model in a circularized phylogenetic tree. I compared the motif accuracy of
the motifs generated from affinity regression with the motifs generated from
a nearest neighbor competitor algorithm by calculating the Kullback-Leibler
divergence (DKL) between the motifs generated from the models and the mo-
tifs calculated directly from the data, which we considered to be ground truth.
Learning from PBM and RNAcompete data, the affinity regression model pre-
dicted the binding affinities of held-out proteins and identified key DNA/RNA-
binding residues associated with binding. More generally, affinity regression
can be used to model biological interaction data as the interactions between the
features of two inputs, and it is possible to apply affinity regression to model
and predict paired macromolecular or cellular interactions in any setting where
there is a high-throughput affinity readout.
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CHAPTER 2
STATISTICAL DATA ANALYSIS OF TUMOR-STROMAL CO-CULTURE
DRUG SCREEN
2.1 Preliminary studies
Rescue scores of stromal-mediated drug resistance
In order to establish the feasibility of using affinity regression to model tumor-
stromal interactions mediating drug resistance, we performed an analysis of the
tumor-stromal co-culture drug screen data taken from Straussman et al. [41].
(Fig 2.1) shows an example of a co-culture experiment from the drug screen.
For each cancer cell line the figure shows (HT-29), a number of stromal cell lines
(HDF, HUVEC, LL86, Wi-38) which are grown in co-culture with and without
the drug (Gemcitabine). There are quadruplicates for each condition and the
measurements of GFP labeled cancer cell counts are averaged over these repli-
cates.
The effect of stromal cells on cancer cells under drug conditions were first
normalized by their effect on cancer cells without the drug. For example, from
the labels in Fig 2.1 the effect of the HDF stromal cells on the HT-29 cancer cells is
given by B/A, that is, the count of cancer cells with drug divided by count of the
cancer cells without drug. Then the rescue score was calculated as the relative
proliferation with stroma minus the relative proliferation without stroma. The
rescue score of cancer cell line HT-29 by stromal cell line HDF is given below:
Rescue(HDF confers to HT-29) =
B
A
− D
C
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Figure 2.1: Rescue of colorectal cancer cell lines from gemcitabine (Gem)
by HDF stromal cells. HT-29 was treated with 0.02 µ M Gemc-
itabine. Fluorescence microscopy looking at GFP positive can-
cer cells at day 7. All 4 quadruplicate wells are shown.
2.1.1 Mean drug rescue score in co-cultures treated with differ-
ent drug dosages
We ran a preliminary statistical analysis of the co-culture drug screen. To iden-
tify drug and dosage combinations that exihibit stromal-mediated rescue of can-
cer cell lines. We calculated an average rescue score for each drug dosage, av-
eraging across all the cancer and stromal co-cultures that were performed for
that drug dosage (Fig. 2.2). We found that stromal cell lines mediate rescue
of cancer cells in many targeted therapies but not for chemotherapeutic drugs.
Chemotherapeutic drugs such as docetaxel, fluorouracil, caboplatin, paclitaxel,
doxorubicin, gemcitabin, etoposize all have low mean rescue score while tar-
geted therapies imatinib, erlotinib, afatinib, gefetinib, vemurafenib all have a
higher range of rescue scores. We found the mean rescue score for PLX4720 in-
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creases as the dosage of PLX4720 increases. Some of the other drugs of interest
include SB590885, another BRAF inhibitor used in the treatment of melanoma.
Since we have several drugs with high mean rescue scores that are either BRAF
inhibitors or MEK inhibitors used in melanoma and we have validation data
pertaining to PLX4720 from the original study, we decided to focus our initial
studies on PLX4720 treated melanoma cell lines.
2.1.2 Dosage comparison of stromal mediated rescue in
melanoma and colorectal co-cultures treated with PLX4720
We plotted the relative proliferation of the cancer cells with stromal cells against
the proliferation of cancer cells without stromal cells in 7 melanoma cell lines
treated with PLX4720 (Fig. 2.3). Here the distance from the diagonal indicates
the magnitude of rescue or sensitization for the drug. We see that higher doses
of the drug cause more killing of cancer cells and therefore lower cell counts
increasing the potential for rescue stromal cells. There is also a bimodality in the
relative proliferation for each set of co-cultures treated with the drug dosage.
We see that for a subset of our cancers the drug has little effect, and there is
also a cluster of cultures with low relative proliferation where the drug has a
large effect. Stromal cells tend to mediate stronger rescue in the higher doses of
PLX4720.
We also plotted the relative proliferation of cancer cells with stroma against
the proliferation of cancer cells without stroma in 5 colorectal cancer cell lines
treated with PLX4720 (Fig. 2.4). There is less drug efficacy of PLX4720, since
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Figure 2.2: Mean drug rescue score averaged across all tumor-stromal co-
cultures indexed by the drug dosage. The average rescue score
for co-cultures treated was calculated and plotted for each drug
dosage.
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colorectal cell lines continue to proliferate even in the presence of PLX4720. We
see that rescue is much greater across melanoma cell lines than across colorec-
tal cell lines where even in cell lines sensitive to the drug with few examples
far from the diagonal. This shows there is a difference in the rescue conferred
by the stromal cell lines to the two different types of cancer cell lines treated
with PLX4720, and stromal cells tend to elicit drug resistance in melanoma cells
against PLX4720.
2.2 Correlation Analysis
2.2.1 Reanalysis of the correlation in cytokine arrays with av-
erage rescue score of melanoma cell lines treated with
PLX4720
To identify the cytokines that are potentially eliciting innate resistance in cancer
cells to targeted drug therapies, we performed a correlation analysis, correlating
cancer cell line rescue scores with the cytokine expression levels secreted by
stromal cell lines. We first calculated the correlations between proteins secreted
by stromal cells and stromal average melanoma rescue scores RM (the average
rescue score over 7 melanoma cell, one for each stromal cell line), reproducing
the results in Straussman et al. to make sure our data analysis is consistent.
Then we performed the correlation analysis with individual cell lines, treating
dosages for each drug separately, and computed the distribution of correlation
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Figure 2.3: Relative proliferation with stroma versus relative prolifer-
ation without stroma in melanoma cancer cell lines. The
relative proliferation of the cancer cells in co-culture with
melanoma cell lines was plotted against the relative prolifer-
ation of cancer cells in monoculture for cancer cell lines treated
with vemurafenib.
scores across the different dosages.
The stromal cell cytokine data set consisted of two types of antibody arrays:
a Human Cytokine Array G4000 and a Biotin Label-based Human Antibody ar-
ray were used to measure proteins secreted into the media by each of 18 stromal
cell types [41]. The arrays measure 274 and 507 secreted proteins respectively.
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Figure 2.4: Relative Proliferation with stroma versus relative prolifera-
tion without stroma in colorectal cancer cell lines. The rel-
ative proliferation of cancer cells in co-culture with colorectal
cell lines was plotted against the relative proliferation of can-
cer cells in monoculture for cancer cell lines treated with vemu-
rafenib.
The resulting antibody arrays were normalized using internal controls and the
values of cytokines in clear media containing 10% FBS were subtracted. After
filtering out the low level cytokine expression values (expression of >50 in at
least one stromal cell line), measurements for 85 and 414 cytokines remained
from each array. A correlation coefficient was calculated for each cytokine be-
tween its log2-transformed secretion level by all 18 stromal cell lines and the
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average melanoma rescue score of each of these cell lines. The mean melanoma
rescue effect of each stromal cell line (RM) was calculated by averaging the res-
cue scores of the this cell line across all melanoma cell lines and all PLX4720
concentrations. If a drug did not reduce proliferation to below 0.3 for a cancer
cell line in monoculture, we removed this drug/cell line pair from the analysis.
After this filtering step, for each cytokine, we correlated the melanoma rescue
score over 18 stromal lines (RM) with the expression level of the cytokines across
these stromal lines. HGF is a prominent cytokine with high correlation with the
mean stromal cell line’s rescue score, but there were also other cytokines with
high correlations such as GDF9 and uPA (with positive correlation) and IL-3
(with negative correlation) (Fig. 2.5, 2.6).
2.2.2 Analysis of the correlation in cytokine arrays with res-
cue scores in individual melanoma cell lines treated with
PLX4720
To examine if there are cytokines other than HGF that contribute to rescue, we
proceeded to perform the correlation analysis with the individual melanoma
cell lines, instead of the averaged stromal rescue score. We also treated the drug
dosages separately and looked at the distribution of correlation scores across
different dosages (Fig. 2.7, 2.8, 2.9, 2.10). Here we show the correlation of HGF
cytokine expression level with PLX4720 at 1µM and 2 µM. We see that HGF
under the drug PLX4720 does score a high median correlation in the cancer cell
lines but is not the only cytokine correlating with the rescue scores. Also there
are cytokines with high negative correlation with rescue such as IL-6 and IL-3
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, suggesting that when these cytokines are present, the targeted therapy may
work more effectively. Other cytokines such as GDF9 and VEGF (with positive
correlation) are potentially interesting as well.
2.2.3 Correlation analysis for cancer subtypes across co-
cultures treated with anticancer drugs
We performed a correlation analysis across 15 anti-cancer drugs and 44 cy-
tokines in the smaller cytokine array. 44 cytokine measurements were obtained
from the normalized cytokine array filtered with an expression cut off of 0.75 af-
ter normalization. We calculated the correlation of the stromal cytokines and the
rescue scores for cancer cell lines across the stromal cell lines. For each cancer
type, we averaged the correlations across all the cancer cell lines of that type to
create an average correlation score. For 44 cyokines in the normalized cyokine
array and across all active drug dosages, we produced a ranked list of pearson
correlation scores for different types of cancer. From our ranked list, the highest
scoring cytokine was GM-CSF whose cytokine secretion was highly correlated
with rescue in melanoma in co-cultures treated with SB590885 4µM with a cor-
relation 0.70 (Fig. 2.11). The next two highest scoring cytokines were HGF in
melanoma cell lines treated with PLX4720 4 µM and 2 µM whose correlations
were both 0.68 (Fig. 2.12, 2.13). The fourth highest scoring cytokine was MMP-
10 in melanoma cell lines treated with PLX4720 1 µM with correlation 0.65 (Fig.
2.14). In breast cancer cell lines, the highest scoring cytokine was VEGF-C in
co-cultures treated with afatinib 0.05 µM (r= 0.58) (Fig. 2.15). In head and neck
cancer cell lines the highest scoring cytokine was MMP-10 in lapatinib 4 µM
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treated cell lines (r= 0.57) (Fig. 2.16). In non-small cell lung cancer the highest
scoring cytokine was HGF in afatinib 0.03 µM treated cell lines (r = 0.54) (Fig.
2.17).
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Figure 2.5: Correlations for each of the cytokines in cytokine array one
with stromal average melanoma rescue score RM. The corre-
lation of the secretion of each cytokine in cytokine array one
with the stromal average rescue score for melanoma cell lines
treated with PLX4720 was calculated. The stromal average res-
cue score for melanoma was calculated for each of the stromal
cell lines as the average rescue score across all melanoma cell
lines in co-culture with the stromal cell line.
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Figure 2.6: Correlations for each of the cytokines in cytokine array two
with stromal average melanoma rescue score RM. The corre-
lation of the secretion of each cytokine in cytokine array one
with the stromal average rescue score for melanoma cell lines
treated with PLX4720 was calculated. The stromal average res-
cue score for melanoma was calculated for each of the stromal
cell lines as the average rescue score across all melanoma cell
lines in co-culture with the stromal cell line.
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Figure 2.7: Box plots of correlations of cytokines secretion in cytokine
array one with rescue of melanoma cell lines treated with
PLX4720 1 µ M. Here we plot box plots of the correlations of
each of the cytokines in cytokine array one with the rescue
scores from the melanoma cell lines under the drug PLX4720
1 µM.
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Figure 2.8: Box plots of correlations of cytokines secretion in cytokine
array two with rescue of melanoma cell lines treated with
PLX4720 1 µ M. Here we plot box plots of the correlations of
each of the cytokines in cytokine array two with the rescue
scores from the melanoma cell lines under the drug PLX4720
1 µM.
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Figure 2.9: Box plots of correlations of cytokines secretion in cytokine
array one with rescue of melanoma cell lines treated with
PLX4720 2 µ M. Here we plot box plots of the correlations of
each of the cytokines in cytokine array one with the rescue
scores from the melanoma cell lines under the drug PLX4720
2 µM.
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Figure 2.10: Box plots of correlations of cytokines secretion in cytokine
array two with rescue of melanoma cell lines treated with
PLX4720 2 µ M. Here we plot box plots of the correlations of
each of the cytokines in cytokine array two with the rescue
scores from the melanoma cell lines under the drug PLX4720
2 µM.
26
−1 0 1 2 3 4
−0.6
−0.4
−0.2
0
0.2
0.4
0.6
0.8
Cytokine Secretion
Re
sc
ue
GM−CSF SB590885 4.0 uM
Melanoma: 0.70
MALME−3M: 0.60
SK−MEL−28: 0.76
SK−MEL−5: 0.74
Correlations
Figure 2.11: Box plots of rescue scores plotted against GM-CSF secretion
in SB590885 4 µM treated melanoma The rescue scores are
plotted as a function of the secretion of GM-CSF secretion in
melanoma cell lines treated with SB590885 4 µM. The average
correlation between the secretion of the cytokine and rescue
scores for cancer cell lines for the cancer subtypes is calcu-
lated.
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Figure 2.12: Box plots of rescue scores plotted against HGF secretion
in vemurafenib 4 µM treated melanoma The rescue scores
are plotted as a function of the secretion of HGF secretion in
melanoma cell lines treated with PLX4720 4 µM. The aver-
age correlation between the secretion of the cytokine and res-
cue scores for cancer cell lines and for the cancer subtypes is
shown.
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Figure 2.13: Box plots of rescue scores plotted against HGF secretion
in vemurafenib 2 µM treated melanoma The rescue scores
are plotted as a function of the secretion of HGF secretion in
melanoma cell lines treated with PLX4720 2 µM. The aver-
age correlation between the secretion of the cytokine and res-
cue scores for cancer cell lines and for the cancer subtypes is
shown.
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Figure 2.14: Box plots of rescue scores plotted against MMP-10 secretion
in vemurafenib 1 µM treated melanoma The rescue scores
are plotted as a function of the secretion of MMP-10 secretion
in melanoma cell lines treated with PLX4720 1 µM. The av-
erage correlation between the secretion of the cytokine and
rescue scores for cancer cell lines and for the cancer subtypes
is shown.
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Figure 2.15: Box plots of rescue scores plotted against VEGF-C secretion
in afatinib 0.05 µM treated breast cancer The rescue scores
are plotted as a function of the secretion of VEGF-C secretion
in breast cancer cell lines treated with afatinib 0.05 µM. The
average correlation between the secretion of the cytokine and
rescue scores for cancer cell lines and for the cancer subtypes
is shown.
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Figure 2.16: Box plots of rescue scores plotted against MMP-10 secretion
in lapatinib 4 µM treated head and neck cancer The rescue
scores are plotted as a function of the secretion of MMP-10
secretion in head and neck cancer cell lines treated with lap-
atinib 4 µM. The average correlation between the secretion of
the cytokine and rescue scores for cancer cell lines and for the
cancer subtypes is shown.
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Figure 2.17: Box plots of rescue scores plotted against HGF secretion in
afatinib 0.03 µM treated non-small cell lung cancer The res-
cue scores are plotted as a function of the secretion of HGF
secretion in non-small cell lung cancer cell lines treated with
afatinib 0.03 µM. The average correlation between the secre-
tion of the cytokine and rescue scores for cancer cell lines and
for the cancer subtypes is shown.
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CHAPTER 3
MODELING TUMOR-STROMAL INTERACTIONS THAT MEDIATE
INNATE RESISTANCE TO TARGETED CANCER THERAPIES
Portions of this chapter first appeared in Yang et al. [30] and were written in
collaboration with Christina Leslie. 1
3.1 Introduction
3.1.1 Background
Cancer is a class of proliferative diseases thought to arise due to a series of so-
matic mutations that result in the dysregulation of cellular pathways. In ad-
dition to cell-intrinsic factors, cancers take place within the context of and are
known to be influenced by extrinsic factors of the surrounding host microen-
vironment. The microenvironment, comprised of innate and adaptive immune
cells, macrophages, fibroblasts, the blood and lymphatic vascular networks and
the extracellular matrix, has been implicated in multiple stages of cancer de-
velopment such as cancer initiation, progression, and metastasis. Cancer cells
have been known to recruit stromal cells in the surrounding microenvironment
to participate in interactions such as reciprocal paracrine signaling that promote
cancer growth and metastatic dissemination to distant organs [26].
Targeted drug therapies, in which a specific molecular target within the con-
text of a cellular mechanism is blocked by a small molecule, represent a sig-
1As per the Cornell dissertation guidelines, the dissertation can include material that has
been previously published or is soon to be published.
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nificant advance in personalized medicine in the genomics era. Oncoprotein-
targeted drug therapy offers a potentially very promising option for cancer
treatment. However, resistance to targeted drug therapies poses a major chal-
lenge to the future success of these treatments. Clinical trials of two recently
popular drugs: imatinib (targeting cells with KIT mutations) and vemurafenib
(targeting BRAFV 600E mutations) both showed patients had marked response
to the drug: 50% response in the case of vemurafenib [22, 27]. These responses,
however, were partial and in most of the cases resistance emerged after a short
period of time eventually leading to cancer relapse. In the case of vemurafenib
tumors recurred within six months of treatment. These short term relapses sug-
gest that mechanisms exist to render a substantial portion of tumor cells resis-
tance to treatment.
Two recent studies have implicated that innate drug resistance may, in part,
be caused by the factors secreted by the tumor microenvironment [41, 48]. The
study by the group at the Broad Institute screened capacity of 23 stromal cell
lines to alter the response of 45 cancer cell lines to 35 commonly used anti-
cancer agents. Of the 23 targeted agents in the panel, there was evidence of
microenvironment-mediated resistance to 15 (65%). The study by the group
at Genentech examined the effect on drug response to eight anti-cancer drugs
of 41 cancer cell lines to exposure to six RTK ligands known to be widely ex-
pressed in tumors. The study showed HGF, FGF, NRG1, and EGF all displayed
a protective effect on the cancer cell lines against the anti-cancer agent, whereas
IGF and PDGF had relatively little effect. The two studies identified HGF as
an important soluble factor that was capable of mediating resistance to BRAF
and HER2 inhibitors. These findings suggest an important role for the tumor
microenvironment in mediating innate drug resistance to molecularly targeted
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therapies.
Although mechanisms of resistance to molecularly targeted therapies are
still not fully understood, one model suggests that cancer cells that are subject to
oncogene addiction can bypass the targeted mechanism through the activation
of alternative pathways, reactivating oncogenic signaling [4, 35, 36, 37, 44, 48].
As cancer cells recruit stromal cells in the tumor microenvironment to promote
cancer growth, stromal cells can potentially participate in this process of con-
ferring resistance by secreting cytokines that can act as upstream activators of
alternative pathways that can reactivate the oncogenic signaling inside the can-
cer cell [30].
Here we model and dissect the interactions between the tumor and stro-
mal cells that mediate innate resistance to target therapies. We will attempt to
understand how cytokines secreted by the stromal cells interact with and acti-
vate alternative pathways in the cancer cells to mediate innate drug resistance
to molecularly targeted therapies. By developing a statistical model to predict
how tumor-stromal interactions give rise to cancer cell proliferation, we will
gain new insights into the role of stromal cells in promoting drug resistance
and ultimately into how we might treat cancer with combination therapies that
target the tumor microenvironment.
3.1.2 Prior Work
Both innate and acquired resistance to molecularly targeted therapies represent
major challenges to cancer treatment. Recent studies have proposed a role for
the tumor microenvironment in therapeutic response, demonstrating that cy-
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tokines secreted by stromal cells can rescue cancer cells from killing by targeted
drugs. To systematically study the stromal contribution to innate drug resis-
tance, we used a method called affinity regression to model the effect of stromal
cells on cancer cell drug sensitivity using a large published stromal-cancer co-
culture data set. Our model represents each stromal cell by the feature vector
of expression levels of its secreted cytokines, and each cancer cell by pathway
scores derived from curated signaling pathway databases, giving a view of the
cellular circuitry that could receive and transduce signals from stromal cells. For
each drug, our algorithm trains a regularized bilinear regression model that pre-
dicts the stromal rescue score for a cancer cell line from stromal and cancer cell
features. We confirmed that affinity regression outperformed nearest neighbor
approaches for the task of predicting rescue scores in cross-validation experi-
ments. Furthermore, by analysis of the trained model, we identified cytokines
secreted by stromal cells that may interact with signaling pathways in cancer
cells to mediate rescue. For the BRAF inhibitor PLX4720, our model identified
HGF as the cytokine most predictive of melanoma cancer cell rescue and asso-
ciated with c-MET and PI3K signaling, consistent with published experimental
reports. Our model also predicted that HGF plays a similar role in non-small cell
lung carcinoma (NSCLC) cells treated with EGFR inhibitors, and we confirmed
this prediction experimentally for afatinib and erlotinib. Our statistical model
of tumor-stromal interactions may lead to new insights into the role of stromal
cells in promoting drug resistance and could ultimately suggest combination
therapies to target the tumor microenvironment.
Tumors are complex tissues that comprise cancer cells as well as diverse stro-
mal cells of the tumor microenvironment (TME) including fibroblasts, endothe-
lial cells, and immune cells along with the extracellular matrix they produce
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[8]. Numerous studies over the past decade have established that the TME
contributes to regulation of tumor initiation, progression, and metastasis [8],
and recent work has begun to elucidate its role in modulating response to ther-
apy [16]. TME-mediated drug resistance includes both innate resistance, re-
sulting from a preexisting network of tumor-stromal interactions that promote
survival/proliferation of cancer cells, and acquired TME resistance, where the
therapeutic intervention leads to changes in the composition or state of cells of
the TME that ultimately protect cancer cells.
In the past several years, large-scale projects in precision oncology have
generated drug dose response data across large panels of molecularly charac-
terized cancer cell lines, with the goal of training predictive models of anti-
cancer drug response [24, 49]. However, these monoculture experiments do
not model the stromal contribution to response to therapy, and therefore the
predictive signatures trained on these data sets may have limited ability to gen-
eralize to patients. Recently, several studies have measured response to can-
cer therapeutics in cancer-stromal cell co-cultures to begin to address the issue
of stromal-mediated innate resistance [41, 42]. While co-culture experiments
cannot model the complex niche established by the TME, they do enable as-
sessment of whether tumor-stromal paracrine signaling alters drug response.
In particular, Straussman et al. generated and analyzed drug dose response
data from cancer cell-stromal cell co-cultures treated with various cytotoxic
and molecularly-targeted drugs and established that hepatocyte growth fac-
tor (HGF), a cytokine secreted by some of the stromal cell lines, could rescue
BRAFV600E mutant melanoma cell lines from killing by the BRAF inhibitor
PLX4720 (an analogue of which, vemurafenib, was recently approved by the
US Food and Drug Administration (FDA) for the treatment of BRAF-mutant
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melanoma) [41]. Another study by Genentech, published at the same time, came
to similar conclusions [48].
Here we revisit the Straussman et al. data set [41] and ask if a more sys-
tematic analysis using machine learning modeling could identify additional se-
creted cytokine-drug pairs that mediate innate drug resistance in cancer cells.
To do this, we applied a multi-task version of affinity regression, a supervised
learning algorithm we recently developed for modeling pairwise biological in-
teractions [21, 40], to drug co-culture experiments. Representing each stromal
cell by a feature vector of its secreted cytokine expression levels and each can-
cer cell by a vector of mRNA expression derived pathway scores, we trained a
regularized bilinear regression model for each drug to predict the rescue score
for each cell line pair (stromal, cancer). Here, the rescue score (introduced pre-
viously, [41]) is a quantitative measure of the extent to which co-culturing with
stromal cells enables increased cancer cell survival/proliferation in the presence
of drug. We used multi-tasking to jointly train across different dosages of the
same drug or different drugs in the same class.
Our affinity regression analysis recovered the finding that HGF can elicit in-
nate resistance in melanoma cell lines treated with BRAF inhibitors. Addition-
ally, we predicted that HGF could also mediate innate resistance in lung cancer
cell lines treated with EGFR inhibitors, and we experimentally confirmed these
predictions for afatinib and erlotinib, two EGFR inhibitors in clinical use in lung
cancer. Our methodology provides a new strategy for mining drug sensitivity
in co-culture data sets and for deciphering innate TME-mediated mechanisms
of drug resistance.
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3.2 Results
3.2.1 Multi-task affinity regression models tumor-stromal in-
teractions in co-culture drug treatment experiments
To uncover stroma-mediated innate drug resistance mechanisms, we interro-
gated co-culture experiments from Straussman et al. [41]. To infer both the cy-
tokines secreted by stromal cells and the signaling pathways in cancer cells that
together mediate drug resistance, we used a supervised machine learning ap-
proach called affinity regression [40]. For each drug and tested dosage, we com-
puted a rescue score, slightly modified from the original study (see Methods),
for each stromal-cancer cell line combination. This score quantifies the prolifera-
tion advantage acquired by cancer cells when co-cultured with the stromal cells
under drug treatment, compared to cancer cells grown in monoculture under
drug treatment. We represented each stromal cell line by the feature vector of
its secreted cytokine expression levels. Expression levels for different cytokines
were not highly correlated. This suggests that it would be unlikely for multiple
cytokines with a similar expression pattern to elicit the drug resistance observed
in the co-cultures. For the cancer cell line representation, we used microarray ex-
pression data for the entire Cancer Cell Line Encyclopedia (CCLE) [24] to define
scores for 75 pathways from the Pathway Interaction Database [6]. Pathways
were also not highly correlated with each other.
Hierarchical clustering of all 1036 cell lines in CCLE by 75 pathway scores
confirmed that pathway information can group cancer cells by their cell type
of origin (Fig. 3.1). Individual pathway scores also provide meaningful char-
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Figure 3.1: Hierarchical clustering of the pathway scores groups cancer
cell lines by tissue of origin (a) Hierarchical clustering of the
pathway scores for 75 curated pathways across 1036 cell lines
from CCLE groups cancer cell lines by tissue of origin and
clusters together growth factor signaling pathways (red) and
cytokine/chemokine mediated pathways (blue). Hematopoi-
etic, stomach, and large intestine cancer cell lines have high
growth factor signaling pathway scores, while lung and skin
cell lines have high cytokine and chemokine mediated path-
way scores. (b) Her2 amplified breast cancer cell lines have
higher ERBB2 signaling pathway scores than Her2 wild type
breast cancer cell lines. (c) Melanoma cell lines with BRAF mu-
tations have higher RAS/RAF signaling pathway scores than
those with wildtype BRAF.
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acterizations of cell line signaling states. For example, Her2-amplified breast
cancer cell lines have higher ERBB2 signaling pathway scores than Her2 wild-
type breast cancer cell lines (Fig. 3.1), while melanoma cell lines with BRAF
mutations have higher RAS/RAF signaling pathway scores the BRAF wild-type
melanoma cell lines (Fig. 3.1). The positive direction of the pathway score de-
termined by principal component analysis (PCA) is given by the direction in
which the majority of the genes are positive. In some cases the majority of the
genes may not give the direction of the up-regulation of the pathway and in this
case our sign convention would not be appropriate. Given this case, choice of
the sign of the pathway is somewhat arbitrary.
We then used affinity regression to learn a bilinear regression model that ex-
plains the rescue scores as interactions between pathway scores of the cancer
cells and cytokine features of the stromal cells (Fig. 3.2). Intuitively, the algo-
rithm learns a weighting over interactions between cancer cell pathway features
and stromal cell cytokine features that explains how these pathway-cytokine
combinations contribute to the observed rescue data. Formally, we set up a bi-
linear regression problem to learn an interaction matrix W between cancer cells,
represented by the input matrix C, and stromal cells, represented by the input
matrix S , that reconstructs the output matrix Y of observed rescue scores (3.2).
Each cancer cell line is represented by its pathway features as a row in C, and
each stromal cell line by its cytokine features as a row in S ; columns in Y rep-
resent the rescue scores of different cancer cells in co-culture with stromal cells.
The affinity regression interaction model is formulated as:
CWS T ≈ Y (3.1)
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Figure 3.2: Affinity regression predicts stromal-mediated rescue from
targeted therapies from cancer cell line pathway scores and
stromal cell cytokine data. (a) Drug co-culture experiments
quantify the extent of stromal-mediated rescue of cancer cells
treated with targeted agents, assigning a rescue score to each
(cancer cell line, stromal cell line, drug/dosage) combination.
(b) Multi-task affinity regression learns to predict rescue scores
from pathway score features of cancer cells and secreted cy-
tokine levels of stromal cells using a regularized bilinear re-
gression strategy. Each task trains on the co-culture experi-
ments for a specific drug and dosage. The model is represented
as an interaction matrix Wt between pathways and cytokines;
S and C represent the feature matrices of cytokine expression
values for stromal cells and pathway scores for cancer cells,
respectively. Tasks corresponding to different dosages of the
same drug or to drugs in the same class are jointly trained by
shrinking model matrices Wt for different tasks towards the av-
erage task Wo.
where C, S , Y are known and W is unknown. We then convert the problem
from a bilinear to a regular regression by taking a tensor product of the input
matrices and solve for W with ridge regression. We perform multi-task affinity
regression for 13 drugs with a focus on two specific drug groups: EGFR and
BRAF/MEK inhibitors. Here, the multiple tasks consist of different dosages for
a specific drug (most targeted drugs were tested at 4 different dose levels) or
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different drugs within a class (e.g. multiple EGFR inhibitors). For each multi-
task regression we add a constraint term to the optimization that shrinks the Wt
task matrices towards a mean Wo matrix.
a
W
Cytokine Mapping
Trained 
model
Cytokines elicit resistance 
in the cancer cells
W
Trained 
model
Stromal cell lineCancer cell line
Pathway Mapping
Pathways receive signals
from the stromal cells
b
Figure 3.3: Cytokine and pathway mappings (a) Multiplying a cancer cell
lines pathway feature vector by the trained model W yields a
vector of cytokine mapping scores. Large positive mapping
scores identify cytokines predicted to mediate innate drug re-
sistance when they interact with the cancer cell line. (b) Mul-
tiplying a stromal cell lines cytokine feature vectors by the
trained model W yields a vector of pathway mapping scores.
Large mapping scores identify cancer pathways whose dysreg-
ulation is predicted to mediate resistance or sensitivity in the
presence of the stromal cell line.
We trained a multi-task affinity regression model on co-culture data for 45
cancer cell lines and 23 stromal cell lines for 35 anti-cancer drugs from the
Straussman et al. study [41], where for each drug, the multiple tasks consisted of
the different drug dosages. We used rescue scores a quantification of cancer cell
proliferation advantage conferred by co-culturing with stromal cells in the pres-
ence of drug as outputs. Our goal was to learn a model for cytokine-topathway
interactions that would generalize to held-out cancer cells, so that we could,
for example, predict the extent of stromal cell-mediated drug resistance (rescue
score) for a test cancer cell line from its pathway score profile.
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3.2.2 Multi-task affinity regression outperforms nearest neigh-
bor methods for predicting rescue in co-culture experi-
ments
In 10-fold cross-validation on held-out co-culture experiments, multi-task affin-
ity regression strongly outperformed prediction based on stromal and cancer
nearest neighbor methods, where the training co-culture experiment that is most
similar to each test example on the basis of Euclidean distance in the cytokine or
pathway feature space is considered the nearest neighbor (P < 2.69 × 10-14 and
P < 4.77 × 10-13, respectively, Wilcoxon signed rank test; Fig. 1e,f). We also
found that multi-task affinity regression strongly outperformed independent
linear regressions across individual tasks in 10-fold cross-validation (P < 8.72
× 108, Wilcoxon signed rank test). These results demonstrate the strong statisti-
cal performance of the tumor-stromal co-culture model learned with multi-task
affinity regression.
In 10-fold cross-validation on held-out co-culture experiments, multi-task
affinity regression strongly outperformed prediction based on stromal and can-
cer nearest neighbor methods, where the training co-culture experiment that is
most similar to each test example on the basis of Euclidean distance in the cy-
tokine or pathway feature space is considered the nearest neighbor (P < 2.69 ×
10-14 and P < 4.77 × 10-13, respectively, Wilcoxon signed rank test; Fig. 3.4).
We also found that multi-task affinity regression strongly outperformed inde-
pendent linear regressions across individual tasks in 10-fold cross-validation
(P < 8.72 × 10-8, Wilcoxon signed rank test). These results demonstrate the
strong statistical performance of the tumor-stromal co-culture model learned
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Figure 3.4: Multi-task affinity regression outperforms nearest-neighbor
methods in 10-fold cross-validation experiments. Models
were trained in multi-task fashion for 54 drug tasks corre-
sponding to multiple dosage levels of 13 anti-cancer therapeu-
tics; pan-EGFR inhibitor and pan-BRAF inhibitor models were
also trained. Multi-task affinity regression strongly outper-
formed (a) cancer nearest neighbor (P < 2.69 × 10-14, Wilcoxon
signed rank test) and (b) stromal nearest neighbor (P < 4.77 ×
10-13, Wilcoxon signed rank test).
with multi-task affinity regression.
3.2.3 Multi-task affinity regression recovers HGF as a stromal
factor that rescues melanoma cells treated with PLX4720
As the affinity regression model captures interaction information between cy-
tokine features of the stromal cells and pathways of cancer cells, we next asked
whether the trained model could identify which cytokines would elicit resis-
tance in specific cancer cells. To achieve this, we trained a model W on all the
46
co-culture data for each drug and mapped each cancer cells pathway scores
through the cytokine-pathway interaction matrix viaCW to get a mapping score
for each cytokine across cancer cell lines (Fig. 3.5). To assess the statistical signif-
icance of the mapping scores at each cytokine-cancer or pathway-stroma pair-
ing, we trained 10,000 affinity regression models for different randomizations of
the rescue scores, used the empirical null distribution of the mapping scores for
each cytokine or pathway to define a nominal P value for the observed scores,
and corrected for multiple tests for each cell line using the Benjamini-Hochberg
procedure.
We then visualized these mapping scores for the PLX4720 model in a
heatmap where significant cytokine-cancer cell interaction scores (FDR < 5%)
are highlighted in orange (resistance) and blue (sensitivity) and (FDR <10%) are
highlighted in dark orange (resistance) and dark blue (sensitivity) (Fig. 3.5). In
the cytokine mapping, the cytokine-cancer interactions that received the highest
scores in this heatmap consisted of a dark red column for HGF in the melanoma
cell lines (Fig. 3.5). TNF-β was a second cytokine that was predicted by the
model to elicit resistance in melanoma cells treated with PLX4720 (Fig. 3.5).
In addition, there were distinct patterns of cytokine-cancer interactions for col-
orectal and melanoma cell lines, suggesting that colorectal and melanoma cells
respond to different stromally-secreted cytokines (Fig. 3.5).
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Figure 3.5: Multi-task affinity regression identifies HGF as the main cy-
tokine that elicits resistance in PLX4720 treated melanoma
cell lines. (a) The heatmap of the cytokine mapping scores
for melanoma and colorectal cell lines using the vemurafenib
model clusters cancer cell lines by subtype. Orange boxes indi-
cate a cytokine-cancer cell line pair significant mapping scores
relative to an empirical null model (FDR < 5%, see Methods)
and dark orange boxes indicate a cytokine-cancer cell line pair
significant mapping scores relative to an empirical null model
(FDR < 10%, see Methods), identifying HGF as the main cy-
tokine that elicits resistance in melanoma cell lines. (b) For each
cytokine, the bar plots show the number of melanoma cell lines
(magenta) for which the mapping score attained significance of
(FDR < 10%). This analysis suggests that stromal-secreted HGF
and TNF-beta frequently mediate resistance to vemurafenib in
lung cancer cells.
48
3.2.4 Affinity regression implicates MET, MYC and PI3K path-
ways in stromal cell-mediated PLX4720 resistance
We next asked whether the trained model could infer which cancer cell path-
ways might receive signals from specific stromal cells to mediate drug resis-
tance. We mapped each stromal cells cytokine expression levels through the
cytokine-pathway interaction matrix, via WS to get a mapping score for each
pathway across stromal cell lines (Fig. 3.6). We constructed a heatmap of
these pathway-stromal mapping scores for PLX4720 treated co-cultures (Fig.
3.6), computed one-sided P values according to a null model similar to before,
and highlighted scores associated with either drug resistance or sensitivity that
passed an FDR threshold of 5% in orange (resistance) and blue (sensitivity) and
FDR threshold of 10% in dark orange (resistance) and dark blue (sensitivity).
Among significant stromal cell-pathway interactions (FDR < 10%) we found
that the MYC pathway was associated with drug resistance in co-cultures with
lung cancer cell lines. We found that the P53 regulation pathway was associated
with drug sensitivity in co-cultures with lung and breast fibroblast cell lines.
Notably, breast, lung, and skin stromal cells have different pathway interaction
profiles based on the mapping score analysis (Fig. 3.6).
Finally, we interrogated the cytokine-pathway interaction matrix W for the
PLX4720 affinity regression model. To assess the statistical significance of the
interaction scores at each cytokine-pathway pairing, we again computed an
empirical null distribution of scores for each cytokine-pathway pair, defined
nominal P values for observed scores, and corrected for multiple tests using the
Benjamini-Hochberg procedure for each cell line. We visualized these interac-
tion scores in a heatmap of PLX4720 cytokine-pathway interactions, where sig-
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Figure 3.6: Multi-task affinity regression implicates the MYC pathway
in drug resistance and P53 regulation pathway in drug sensi-
tivity in PLX4720 treated cell lines. The heatmap of the path-
way mapping scores for breast, skin, and lung fibroblasts using
the vemurafenib model clusters stromal cell lines by their tis-
sue of origin. Dark orange boxes indicate pairs whose map-
ping scores are significantly associated with drug resistance
and dark blue boxes indicate pairs whose mapping scores are
significantly associated with drug sensitivity (FDR <10%). This
analysis implicates the MYC pathway in drug resistance and
the P53 regulation pathway in drug sensitivity mediated by
lung and breast fibroblasts.
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Figure 3.7: Multi-task affinity regression identifies the HGF and MET
pathway and HGF and PI3K and PI3K/AKT pathways in
drug resistance against vemurafenib The heatmap of absolute
values of cytokine-pathway interactions in the model matrix
W. Orange boxes indicate cytokine-pathway interactions that
are significant relative to an empirical null model (FDR < 5%,
see Methods) and dark orange boxes indicate (FDR < 10%, see
Methods) and identify (HGF, MET pathway) and (HGF, PI3K
pathway) and (HGF, PI3K/AKT pathway) as significant inter-
actions.
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nificant cytokine-pathway interactions (FDR < 5%) are highlighted in orange
and (FDR < 10%) are highlighted in dark orange (Fig. 3.7). The cytokine-
pathway interactions that received the highest scores were those that interacted
with HGF, including the MET pathway, which is the receptor for HGF [10, 43],
and the PI3K and PI3K/AKT pathway, which has been shown to be involved in
HGF reactivation of oncogenic signaling in breast cancer cell lines treated with
lapatinib and lung cancer cells treated with erlotinib [48].
3.2.5 Multi-task training learns a pan-EGFR inhibitor model of
stromal-mediated resistance
After confirming that our model recovered the known biology of stromal-
mediated resistance to PLX4720, we next turned to co-cultures treated with
EGFR inhibitors. We trained separate multi-task affinity regression models on
co-culture experiments with afatinib, canertinib, erlotinib, gefitinib, CL-387785,
and lapatinib, where each model included data for multiple dosage levels of
each drug. In addition, we trained a pan-EGFR model involving a subset of
EGFR inhibitors with enriched activity against EGFR over other tyrosine ki-
nases, including: afatinib, erlotinib, gefitinib, and CL-387785. Meanwhile caner-
tinib, targeting EGFR, HER-2, and ErbB-4, and lapatinib, targeting EGFR and
HER-2, were excluded as they inhibit multiple tyrosine kinases [5].
We then asked whether we could identify stromal-secreted cytokines con-
tributing to drug resistance, as we did for the BRAF inhibitor PLX4720. To do
this, we mapped the cancer pathways profile through the interaction matrix of
the trained model (CW) to obtain a cytokine-cancer cell line mapping for indi-
52
aAfatinib
c
Cell Counts
Breast Lung
Ca
nc
er
 S
ub
typ
e
He
r2
 P
os
itiv
e LA
P
Os
te
op
ro
te
ge
rin
G
M
−C
S
F
M
C
P
−1
G
D
F−
15
M
C
P
−3
GR
O
D
K
K
−1
TI
M
P
−1
H
G
F
IL
−8
S
D
F−
1
M
M
P
−1
0
TN
F−
be
ta
IL
−6
TI
M
P
−2
D
K
K
−3
DP
PI
V
M
M
P
−1
De
co
rin
 
IL
−2
 R
 a
lp
ha
 1
FL
R
G
B
at
e2
 M
Fo
lli
st
at
in
C
at
he
ps
in
 S
IC
A
M
−2
PA
I−
I
IL
−1
 R
4 
/ S
T2
P
D
G
F 
A
A
IL
−3
FG
F−
6
IL
−1
 a
lp
ha
bF
G
F
M
IP
−3
 a
lp
ha
N
id
og
en
−1
G
C
S
F
GR
O
−a
lp
ha
IL
−1
 b
et
a
M
IP
−1
 a
lp
ha
IG
FB
P
−6
V
E
G
F−
C
IG
F−
II
An
gi
og
en
in
uP
AR
HCC2935
HCC4006
HCC827
NCI−H3255
HCC1569
MDA−MB−361
EFM192A
HCC1419
SK−BR−3
BT−474
MDA−MB−175−VII
−0.02 0.02 0.06
Breast
NSCLC
Her2 Positive
Her2 Negative
3 2 1 0 1 2 3 4 5
IL−2 R alpha 1
MMP−1
DPPIV
IL−8
HGF
Figure 3.8: Multi-task affinity regression identifies the HGF in drug re-
sistance in afatnib treated co-cultures (a) The heatmap shows
cytokine mapping scores for breast cancer and non-small cell
lung cancer (NSCLC) cells lines for the afatinib affinity regres-
sion model. Orange boxes indicate cytokine-cancer cell line
pairs that are significantly associated with drug resistance rel-
ative to an empirical null model (FDR < 5% ), while dark or-
ange boxes indicate (FDR < 10%). (b) For each cytokine, the bar
plots show the number of breast cancer cell lines (red) and the
number of lung cancer cell lines (black) for which the mapping
score attained significance. This analysis suggests that stromal-
secreted HGF and IL-8 frequently mediate resistance to afatinib
in lung cancer cells, but seldom in breast cancer cells.
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Figure 3.9: Multi-task affinity regression identifies the HGF in drug re-
sistance in pan-EGFR inhibitor model (a) The heatmap shows
cytokine mapping scores for breast cancer, NSCLC, and head
and neck squamous cell carcinoma (HNSCC) cell lines for the
pan-EGFR affinity regression model with multi-task training
across gefitinib, afatinib, erlotinib, and CL-387785 (b) For each
cytokine, the bar plots show the number of breast cancer cell
lines (red) and the number of lung cancer cell lines (black)
for which the mapping score attained significance for the pan-
EGFR affinity regression model. The analysis suggests that
HGF and IL-8 frequently mediate resistance to EGFR inhibitors
in lung cancer cells, while MMP-1 mediates resistance in breast
cancer cells.
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vidual and the pan-EGFR inhibitor models. The cytokine-cancer cell mapping
scores for the afatinib and pan-EGFR models, where we again used an empirical
null model to assess the significance of high-scoring mapping scores and high-
lighted cytokine-cancer cell line interactions that satisfied an FDR < 5% thresh-
old in orange and FDR < 10% in dark orange (Fig. 3.8, 3.9). Then we counted
the number of breast cancer and lung cancer cell lines with a significant inter-
action for a cytokine (Fig 3.8, 3.9). Notably, this analysis suggested that HGF
and IL-8 elicit resistance to afatinib and EGFR inhibitors in non-small cell lung
cancer cells, but seldom in breast cancer cells (Fig. 3.8, 3.9).
3.2.6 Experimental validation confirms HGF as a novel stro-
mal factor mediating resistance to afatinib and erlotinib
in non-small cell lung cancer cells
Finally, to experimentally assess predictions from the affinity regression model-
ing of EGFR inhibitors, we tested the ability of HGF to rescue cancer cell prolif-
eration in lung cancer cell lines treated with afatinib and erlotinib.
To do this, we cultured three NSCLC cell lines HCC4006, HCC2935, and
HCC827 all of which were also included in the Straussman et al. co-culture
data sets and performed dose response experiments to afatinib and erlotinib in
the presence or absence of HGF (Fig. 3.10). In all cases, we confirmed that HGF
conferred rescue to the afatinib and erlotinib treated NSCLC cell lines.
Dose response curves in the presence of drug only (blue) or drug with HGF
(red) as well as the relative cancer proliferation at the dose with maximal rescue
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Signicance of HGF mediated resistance to EGFR inhibitors in Non-Small Cell Lung Cancer
Tumor Cells Cytokine
Anti-cancer drug
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Figure 3.10: Summary of HGF mediated drug resistance non-small cell
lung cancer cell lines Summary of drug resistance experi-
ments comparing cancer cell line proliferation under treat-
ment with two EGFR inhibitors, afatinib and erlotinib, across
3 NSCLC cell lines with and without HGF. The P value indi-
cates the most significant increase in cancer cell counts over
the drug dose response experiments in drug+HGF versus
drug only conditions.
are shown from specific examples (dose response for HCC4006 with afatinib
concentrations 0.49 nM 2000 nM and relative abundance at 31 nM; HCC2935
with afatinib concentrations 31 nM 2000 nM and at 32 nM; HCC4006 with er-
lotinib concentrations 6.4 nM 20000 nM and at 32 nM; HCC2935 with erlotinib
concentrations 0.05 nM 20000 nM and at 32 nM), Fig. 3.11.
3.3 Methods
3.3.1 Rescue score calculation
We adapted the rescue score associated with drugs in tumor-stromal co-culture
experiments as previously defined by Straussman et al. [41]. The original study
provided data on cancer cell proliferation under drug treatment as the normal-
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Figure 3.11: Dose response curves and relative abundance of cancer pro-
liferation at a specific drug dose for HGF mediated drug re-
sistance in non-small cell lung cancer cell lines (b,d,f,h) Dose
response curves for drug+HGF (red) versus drug only (blue)
for specific NSCLC cell lines, plotting relative abundance of
cancer cells as a function of drug dose with HGF concentra-
tion fixed. Experiments are performed in triplicate. (c,e,g,i)
Relative abundance of cancer cells at a specific drug dose (as
shown), showing baseline, HGF only, drug only, and HGF val-
ues.
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ized GFP cell count of cancer cells in monoculture (M) and co-culture with stro-
mal cells (C). We calculated a proliferation pseudocount p that was approxi-
mately 0.65 and saw that the choice of pseudocounts did not largely affect the
performance of the model. We defined the rescue score R as the difference of log
transformed. We computed Z-scores from the resulting values to get the new
rescue scores:
R = log2(M + p) − log2(C + p). (3.2)
3.3.2 Cytokine array processing
We obtained cytokine expression levels from the Human Cytokine Array G4000
(RayBio, AAH-CYT-G4000-8) from the Straussman et al. study [41]. We shifted
the entire distribution of cytokine expression levels by adding the minimum
value plus 1, and log10-transformed the resulting values. Then we converted
the cytokine expression values to Z-scores. Finally, we filtered out cytokines
whose maximum Z-score was less than 0.75; the Z-scores for the remaining cy-
tokines gave the stromal input matrix used in training the model.
3.3.3 Pathway scores
We performed standard RMA normalization on microarray gene expression
data of 1036 cancer cell lines available through the Cancer Cell Line Encyclo-
pedia (CCLE). We curated 75 relevant pathways from the Pathway Interaction
Database available through the GSEA web resource, selecting signal transduc-
tion and oncogenic pathways. For the 39 cancer cell lines in the co-culture exper-
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iments with expression data in CCLE, we calculated pathway scores as follows.
For each pathway, we restricted the expression matrix of all 1036 CCLE cancer
cell lines to the genes in the pathway, performed PCA on this reduced expres-
sion matrix, and took the coordinate of each cell line relative to the first principal
component as its pathway score. Since the sign of the coordinate is arbitrary, we
took the positive direction to be the one where the larger number of genes in
the pathway had a positive sign. For the final pathway score input matrix, the
vector of pathway scores for each cancer cell line was unit normalized.
3.3.4 Multi-task affinity regression
We modeled the interaction between cancer and stromal cells and their molec-
ular components in co-culture under drug treatment using a bilinear regression
method called affinity regression [40]. In this approach, we try to model how the
stromal cells signal to the cancer cells through secreted cytokines and how can-
cer cells receive the signals through activated signaling pathways. Affinity re-
gression predicts the rescue scores based on interactions between the cancer cell
line pathway scores and stromal cell line cytokine expression levels. Since co-
culture experiments treated with different drug dosages had been performed,
we jointly learned from multiple dosage experiments using a multi-task version
of affinity regression.
argminW
T∑
t=1
‖vec(Yt) − (S t ⊗Ct)vec(Wt)‖22 + ρ1
T∑
t=1
‖vec(Wt) −Wo‖22 + ρ2
T∑
t=1
‖vec(Wt)‖22
(3.3)
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Wo =
1
T
T∑
s=1
Ws (3.4)
A reconstruction of the optimal common task model is given by
W∗o =
ρ1
ρ1 + ρ2
1
T
T∑
t=1
W∗t (3.5)
3.3.5 Parameter optimization
We trained multi-task affinity regression for 13 targeted drug therapies and 2
larger drug groups consisting of EGFR and BRAF inhibitors, comprising a total
of 54 different co-culture experiments across the different training sets. For each
model, we performed a parameter grid search for the optimal parameters ρ1 and
ρ2, varying ρ1 from 0.00001 to 10000 and ρ2 from 0.00001 to 10000. We narrowed
down the parameter space for both ρ1 and ρ2 to a range of 9 parameter values
and performed nested 10-fold cross-validation.
We performed a nested 10-fold cross-validation of the multi-task affinity re-
gression. For each fold of the outer 10-fold cross-validation, we performed a
grid search across 9x9 parameter pairs (ρ1 and ρ2). We took the median of me-
dian parameter values to obtain our optimal parameter pair from nested 10-
fold cross-validation. Using this parameter choice we calculated the mean task-
specific Spearman correlation performance for all 54 drug dosages.
60
3.3.6 Comparison of multi-task with single-task affinity regres-
sion
We compared the performance of our task specific predictions of our multi-task
affinity regression with the performance of least squares affinity regression on
the tasks or 54 drug dosages as separate regressions. We constrained the least
squares optimization with a L2 regularizer where we varied the regression pa-
rameter ρ from 0.0001 to 100 incrementally by orders of 10 magnitudes. We
performed a nested 10-fold cross-validation of the least squares affinity regres-
sion and obtain a mean Spearman correlation as a measure of performance in
the outer 10-fold cross-validation for each of 54 drug dosages across 13 drugs
and 2 larger drug groups.
3.3.7 Comparison of multi-task affinity regression with nearest
neighbor methods
The stromal nearest neighbor algorithm finds the predicted rescue score for a
held-out drug co-culture experiment by reporting the rescue score of the train-
ing co-culture experiment with the stromal cell line that is the closest in Eu-
clidean distance in the stromal feature space and with the same cancer cell line.
Similarly, the cancer nearest neighbor algorithm finds the predicted rescue score
by reporting the rescue score of the training co-culture experiment with the can-
cer cell line that is the closest cancer cell line in cancer feature space and with the
same stromal cell line. We compared the Spearman correlation of the predictions
in the 54 drug/dosage data sets to the experimental rescue values in multi-task
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affinity regression to cancer and stromal nearest neighbor algorithms.
For each comparison of the Spearman correlations between the multi-task
affinity regression and nearest neighbor from 54 drug/dosage experiments, we
performed a Wilcoxon signed rank test to see if multi-task affinity regression
outperforms nearest neighbor in Spearman correlation.
3.3.8 Empirical null models
For assessing the significance of cytokine-cancer cell line mapping scores, we
generated 10,000 randomized data sets where we permuted the rescue scores
of the response variable Y . We permuted the rescue scores for each stromal
cell line and then we permuted the stromal cell lines. Then we trained 10,000
multi-task affinity regression models and mapped the W interaction matrices
onto the cancer matrix C. For each cytokine-cancer mapped value, its empirical
p-value is the fraction of randomly generated mapping values more extreme
than that value out of the distribution of randomly generated mapping val-
ues for that cytokine-cancer pair. We obtained p-values for both the left-hand
sides and right hand-sides of the distributions. The left hand side tested for a
cytokine-cancer or pathway-stromal interactions sensitivity to the drug and the
right hand side tested for resistance to the drug. We corrected for FDR in multi-
ple hypothesis testing of cytokine-cancer mapping values for each cell line sep-
arately using the Benjamini-Hochberg procedure. Pathway-stromal mapping P
values were computed in an analogous fashion, again with Benjamini-Hochberg
FDR correction applied for each stromal cell line separately.
For assessing the significance of cytokine-pathway interaction weights in the
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W matrix, we generated random 10,000 data sets where we permuted the res-
cue scores in the response variable Y . We permuted the rescue scores for each
stromal cell line and then we permuted the stromal cell lines. Then we ran
10,000 multi-task affinity regression models and obtained the W interaction ma-
trices. For each cytokine-pathway interaction value, its empirical p-value is the
number of randomly generated interaction values found more extreme than that
value over the total number of randomly generated interaction values for that
cytokine-pathway interaction.
We performed a Benjamini-Hochberg FDR correction for the set of P values
associated with each cytokine separately.
3.3.9 Cells, inhibitors, and cytokines
HCC827, HCC4006 and HCC2935 cells were a kind gift from the lab of Marc
Ladanyi (MSKCC). Cells were maintained in DMEM with 10% fetal bovine
serum, penicillin and streptomycin. HGF-1 (peprotech) was dissolved in
PBS+0.5% BSA was used at 50 ng/ml. Erlotinib and afatinib were purchased
from Sellechem and used at an assay dependent concentration as indicated. For
drug and cytokine treatment, 5,000 cells were plated per well in a 96 well plate
with DMEM+10%FBS. Growth was measured in triplicate following 72 hours
of drug/cytokine treatment using an MTT assay per the manufacturers instruc-
tions (Roche). The experimental validation was performed by Dr. Robert L.
Bowman in Dr. Johanna Joyce’s lab at Memorial Sloan Kettering cancer center.
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3.4 Conclusion
We have presented a new supervised learning strategy for modeling cancer-
stromal cell paracrine signaling from co-culture anti-cancer drug sensitivity ex-
periments. Using an expression-based pathway feature representation for can-
cer cells and a cytokine expression level representation for stromal cells, we
trained affinity regression models to predict stromal-mediated rescue scores of
cancer cells for each drug; we employed a multi-task strategy to share informa-
tion across models for different dosages of the same drug or different drugs of
the same class. As a bilinear regression model, affinity regression allows us to
define feature space mappings using the trained model. The mappings identi-
fied the cytokines that are most strongly associated with resistance/sensitivity
for each cancer cell line, as well as the cancer cell pathways that appear to me-
diate resistance/sensitivity for each stromal cell line. Through an empirical null
model, we assigned statistical significance to these key predicted features. This
analysis recovered the published finding that stromal-derived HGF mediates
resistance to BRAF inhibitors in melanoma cell lines. Moreover, our affinity
regression analysis predicted that HGF would mediate resistance to EGFR in-
hibitors in lung cancer cell lines. Follow-up cell culture experiments with afa-
tinib and erlonitib confirmed this clinically relevant prediction.
The largest limitation of our study is the small training data set size. Ide-
ally, we would use on the order of 100 stromal and cancer cell lines with a
full matrix of co-culture experiments as training data for each drug/dosage;
in practice, the co-culture matrix used consisted of 10-20 cancer cell lines by a
similar number of stromal cell lines, and a different matrix of co-cultures was
assayed for each drug [41]. While our multi-task strategy helps improve model
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accuracy in this low training data setting, it cannot fully address the fact that
we are not adequately sampling the space of cancer-stromal interactions. As a
secondary issue, the mRNA expression signature representation of cancer was
also predicated on data availability; phosphoproteomic data might be more di-
rectly relevant as a representation of active signaling pathways in cancer cells,
but while data resources based on technologies like reverse-phase protein array
[25] and mass spectrometry [31] are increasing, the overlap with the cancer cell
lines in our study remains limited. Nevertheless, the current work provides an
important proof-of-principle that supervised learning can indeed derive novel
findings from co-culture drug sensitivity data sets, providing a path forward for
future larger-scale studies.
3.5 Comparison of multi-task affinity regression to multi-task
pairwise SVM
3.5.1 Optimization Problem for Pairwise SVM
Support Vector Machines are classification algorithms that learn a linear deci-
sion rule based on maximizing a margin [3]. Different mappings x 7→ Φ(x) ∈ H
construct different SVMs. The mapping Φ(·) is implicitly performed by a kernel
function K(·, ·) which defines an inner product in H. The decision function given
by an SVM can be described by:
f (x) = w · Φ(x) + b =
∑
i
αiyiK(xi, x) + b
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(3.6)
The optimal hyperplane is the one with maximal distance (in H space) to the
closest image Φ(xi) from the training data (called the maximal margin). This
reduces to the following dual optimization problem:
arg αmax
m∑
i=1
αi − 12
m∑
i, j=1
αiα jyiy jK(xi, x j)
(3.7)
subject to:
0 ≤ αi ≤ C,∑mi=1 αiyi = 0, i = {1, ...,m}
In affinity regression, our examples consist of each (i, j) tumor-stromal pair and
our regression features consist of the pairwise products of the features of each
input matrix given by v j ⊗ ui. We set up an equivalent SVM formulation in
this feature space. For this purpose, we discretize our response variable Y such
that yi j ∈ {+1,−1}. Our w is now the normal to the hyperplane that divides the
training examples with the maximum margin.
Y = w · X =⇒ yi, j = w · (v j ⊗ ui)
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(3.8)
To obtain the w with the maximum margin we solve this optimization problem:
arg w, ξmin
1
2
‖ w ‖2 +C
m∑
i=1
n∑
j=1
ξi, j
(3.9)
subject to:
yi, j(w · (v j ⊗ ui)) ≥ 1 − ξi, j, ξi, j ≥ 0, i = {1, ...,m}, j = {1, ..., n}
It can be shown that the w is a linear combination of the feature vectors of the
examples.
w =
∑
s,t
αs,tys,t(vs ⊗ ut)
(3.10)
substituting the for w in the expression for yi, j (Equation 4.3) we get:
yi, j =
∑
s,t
αs,tys,t(vs ⊗ ut)(v j ⊗ ui)
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(3.11)
We use the tensor kernel:
K((vi, u j), (ut, vs)) = (v j ⊗ ui)(vs ⊗ ut)
(3.12)
Furthermore if we distribute the terms vi and us through the kronecker product,
we get:
yi, j =
∑
s,t
αs,tys,t(v j ⊗ ui)(vs ⊗ ut) =
∑
s,t
αs,tys,t(v j · us) · (vi · ut)
(3.13)
The affinity regression model can be formulated as a pairwise SVM where the
tasks are symmetric and can either be on the cancer side or on the stromal side.
K((ui, v j), (ut, vs)) = Kv(v j, vs) · Ku(ui, ut)
(3.14)
where:
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Kv(v j, vs) = v j · vs
Ku(ui, ut) = ui · ut
(3.15)
Kv is the Kernel for similarities between stromal cell lines.
Ku is the Kernel for the similarities between cancer cell lines.
3.5.2 Primal Optimization Problem for Multi-task Pairwise
SVM
To multi-task the pairwise SVM, we turn to the multi-task formulation in the
Evgeniou and Pontil paper [46]. We solve this optimization problem:
arg wt, ξi, j,t min ρ1
∑T
t=1 ‖ wt ‖2 +ρ2
∑T
t=1 ‖ wt −
1
T
T∑
s=1
ws ‖2 +
T∑
t=1
m∑
i=1
n∑
j=1
ξi, j,t
(3.16)
subject to:
yi, j,t(wt · (v j,t ⊗ ui,t)) ≥ 1 − ξi, j,t, ξi, j,t ≥ 0, i = {1, ...,m}, j = {1, ..., n}, t = {1, ...,T }
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3.5.3 Dual Optimization Problem for Multi-task Pairwise SVM
Let
C:=
1
2 · ρ1 + ρ2 , µ :=
Tρ1
ρ2
,(3.17)
and define the kernel
Ks,t((v j ⊗ ui), (vl ⊗ uk)) := (1
µ
+ δs,t)(v j ⊗ ui) · (vl ⊗ uk) (3.18)
where i, k ∈ {1, 2, ...,m}, j, l ∈ {1, 2, ..., n}, and s, t ∈ {1, 2, ...,T }
The dual problem of (Equation 4. 11) is given by
arg αi, j,t max
∑m
i=1
∑n
j=1
∑T
t=1 αi, j,t −
1
2
m∑
i=1
n∑
j=1
T∑
s=1
m∑
k=1
n∑
l=1
T∑
t=1
αi, j,syi, j,sαk,l,tyk,l,tKs,t((v j,s ⊗
ui,s), (vl,t ⊗ uk,t))
(3.19)
subject, for all i, k ∈ {1, 2, ...,m}, j, l ∈ {1, 2, ..., n}, and s, t ∈ {1, 2, ...,T }, to the con-
straints that the constraint that 0 ≤ αi, j,t ≤ C.
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3.6 Performance Comparison of multi-task affinity regression
to multi-task pairwise SVM
I compared the performance of multi-task affinity regression with the multi-
task pairwise SVM using 10-fold cross-validation on the co-culture drug screen
data set. I created labels from the rescue scores by taking rescue scores > 0.6 as
my positive labels and rescue scores < 0.2 as my negative labels. Here a posi-
tive label means there was drug resistance conferred to the cancer cells by the
stromal cells in co-culture and a negative label means no drug resistance was
conferred. I ran the multi-task pairwise SVM models across co-cultures treated
with different drug dosages for 13 anti-cancer drugs and across different drugs
for two drug groups: the BRAF/MEK and EGFR inhibitors using 10-fold cross-
validation. For comparison with affinity regression, I calculated an AUC for
the corresponding multi-task affinity regression models by converting the con-
tinuous rescue scores to positive and negative labels as described above and
then calculated the AUC for the predicted rescue scores from affinity regres-
sion. Here I show the comparison in performance for the two methods for some
example drugs: PLX4720, afatinib, erlotinib, and gefinitib. Finally, I show the
overall comparison of AUCs for all 13 drugs and the two drug groups. Multi-
task affinity regression outperforms multi-task pairwise SVM (P < 3.05 × 10-4,
Wilcoxon signed rank test). The AUC for both methods were high. If we adopt
a nonlinear Gaussian or polynomial kernel the pairwise SVM could possibly
outperform affinity regression.
71
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
False positive rate
Tr
ue
 p
os
itiv
e 
ra
te
Multi−task Pairwise SVM AUC: 0.89
Multi−task Affinity Regression AUC: 0.93
PLX4720 drug resistance in cocultures performance
Figure 3.12: Comparison of multi-task affinity regression with multi-
task pairwise SVM in PLX4720 drug resistance Multi-task
affinity regression (AUC = 0.93) outperforms multi-task pair-
wise SVM (AUC = 0.89). Models were assessed using 10-fold
cross-validation.
72
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
False positive rate
Tr
ue
 p
os
itiv
e 
ra
te
Multi−task Pairwise SVM AUC: 0.72
Multi−task Affinity Regression AUC: 0.94
Afatinib drug resistance in cocultures performance
Figure 3.13: Comparison of multi-task affinity regression with multi-
task pairwise SVM in afatinib drug resistance Multi-task
affinity regression (AUC = 0.94) outperforms multi-task pair-
wise SVM (AUC = 0.72). Models were assessed using 10-fold
cross-validation.
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Figure 3.14: Comparison of multi-task affinity regression with multi-
task pairwise SVM in erlotinib drug resistance Multi-task
affinity regression (AUC = 0.95) outperforms multi-task pair-
wise SVM (AUC = 0.85). Models were assessed using 10-fold
cross-validation.
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Figure 3.15: Comparison of multi-task affinity regression with multi-
task pairwise SVM in gefitinib drug resistance Multi-task
affinity regression (AUC = 0.91) outperforms multi-task pair-
wise SVM (AUC = 0.86). Models were assessed using 10-fold
cross-validation.
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Figure 3.16: Comparison of multi-task affinity regression with multi-
task pairwise SVM AUC performance in 13 drugs and
2 drug groups. Multi-task affinity regression outperforms
multi-task pairwise SVM in AUC (P < 3.05 × 10-4, Wilcoxon
signed rank test). Models were assessed using 10-fold cross-
validation.
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CHAPTER 4
APPLICATION OF AFFINITY REGRESSION TO PBM AND
RNACOMPETE DATA
4.1 Application of affinity regression to PBM and RNAcompete
data
4.1.1 Affinity regression modeling of TF/RBP and DNA/RNA
interactions in PBM and RNAcompete data
We used affinity regression in another context to analyze PBM and RNAcom-
pete data sets. In PBM experiments, the DNA-binding preferences of an in-
dividual fluorescently tagged TF are measured using a universal array of >40K
double-stranded DNA probes [12]. In the RNAcompete assay, the binding affin-
ity of an RBP is measured against >200K single-stranded RNA probes [13, 14].
In our 2015 affinity regression paper [40], we used affinity regression to learn
the DNA or RNA recognition code for families of TFs or RBPs directly from the
protein sequence and probe-level binding data from PBM or RNAcompete ex-
periments. In this context, affinity regression trains on PBM or RNAcompete
experiments to learn an interaction model between proteins and nucleic acids.
Learning from PBM or RNAcompete data for diverse TFs and RBPs, the affin-
ity regression model can predict the binding affinities of held-out proteins and
identify key DNA/RNA-binding residues.
In this project, I prepared the input data and generated and analyzed the
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motifs for affinity regression models trained on RNAcompete data and gener-
ated motifs for affinity regression models for PBM data. I obtained the amino
acid sequences of protein binding domains of 207 RBPs. I computed the amino
acid 4-mer count matrix for the protein binding domain input sequences of the
RBPs. I also created the nucleotide 5-mer count matrix for the nucleic acid in-
put sequences of the RNA probes. I then extracted and normalized the matrix
of binding affinities of the RBPs to the RNA probes. These data were then in-
put into the affinity regression algorithm to learn the binding affinities of the
RBPs to the RNA probes as a function of the interactions between the K-mer
features of the protein domain sequences and nucleotide k-mer features of the
RNA probes.
Binding models can be trained either from probe level measurements or 8-
mer/7-mer summarizations of the PBM/RNAcompete probe-level data. We
also trained two affinity regression models from the 7-mer Z-score summariza-
tions of the probe-level data using Z-scores as reported on the cisBP-RNA web-
site and the from the PBM data set. After the modeling was done for the Z-score
models, I plotted an example of the experimental and affinity regression pre-
dicted Z-scores for SNAPOd2T00005194001, a mouse homeodomain from the
PBM data set, showing the top 100 affinity regression predicted 8-mers versus
the top 100 experimental 8-mers and the enrichment of top experimental 8-mers
in the predicted set. I generated motifs from the DNA/RNA-binding residues
of probes that were associated with high Z-scores from the Z-score models. For
the RBP Z-score model, I evaluated how well affinity regression was able to re-
cover these motifs by comparing the motifs obtained from affinity regression
against the motifs obtained from a nearest neighbor competitor algorithm and
motifs obtained directly from the RNAcompete assay, which we considered as
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the ground truth. I compared the Kullback-Leibler divergence (DKL) of the affin-
ity regression motifs with the DKL of nearest neighbor motifs against motifs ob-
tained from the RNAcompete assay.
4.1.2 Example of predicted Z-scores
(Fig. 4.1) shows an example of predicted versus experimental 8-mer Z-scores
for an Oikopleura dioica homeodomain SNAPOd2T00005194001 assayed by
Weirauch et al. [15]. The overall rank correlation of predicted and experimen-
tal Z-scores is high (Spearman ρ = .765), and 48% of the top 100 8-mers based
on predicted Z-scores overlap with the top 100 8-mers determined from exper-
imental Z-scores. Moreover, running the PWM-Align-Z algorithm on top 100
predicted 8-mers produces a motif similar to the one obtained from the top ex-
perimental 8-mers.
4.1.3 Motif visualization and comparison of affinity regression
motifs with nearest neighbor motifs
For the RBP data set, using 10-fold cross-validation, we trained a Z-score model
using 7-mer Z-scores (as reported in Ray et al. (2013) [14]), predicted the top 100
7-mers for held-out RBPs, and used these as input to our motif prediction al-
gorithm PWM-Align-Z. For the RNA motif prediction, we used PWM-Align-Z
to produce a position weight matrix (PWM) for each RBP RNAcompete exper-
iment. We used the top 100 7-mers with highest predicted Z-scores as input
to PWM-Align-Z to generate binding motifs. We found the choice of 7-mer Z-
79
Predicted Motif
Experimental Motif
−2 0 2 4 6 8
−2
−1
0
1
2
3
4
5
6
Experimental Z-scores
Pr
ed
ic
te
d 
Z-
sc
or
es
SNAPOd2T00005194001 
ACATGTAC
ACATGTAT
ATTACATG
TACATGTA
ACATGTAA
ATGTACAT
AACATGTA
ATTACAAG
GTACAAGA
TAACATGA
ACATGTTG
All 8-mers
Top 100 predicted 8-mers
Overlap top 8-mers
Top 100 8-mers
Figure 4.1: Example of homeodomain predicted versus experimen-
tal Z-scores. Example of predicted Z-scores from the Z-
score affinity regression model, trained on 75 non-redundant
mouse homeodomains, versus experimental Z-scores for SNA-
POd2T00005194001, one of the diverse homeodomains assayed
by Weirauch et al. [15] Binding motifs generated by PWM-
Align-Z based on the top 100 8-mers predicted by affinity re-
gression and the top 100 8-mers based on actual Z-scores are
shown.
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scores and top 100 7-mers for motif summarization to generate reproducible and
reasonably high information content motifs across replicates. We visualized the
PWMs from 207 RBPs, including both RRM and KH subfamilies using the motif-
Stack (version 1.4.0) R package and plotted them in a circularized phylogenetic
tree (Fig. 4.2).
4.1.4 Comparison of Kullback-Leibler divergence of affinity re-
gression motifs with nearest neighbor motifs
I calculated the Kullback-Leibler divergence (DKL) between the motifs gener-
ated from affinity regression and from the nearest neighbor algorithm and the
ground truth motifs [40]. For each RBP we took its motif generated from affin-
ity regression or nearest neighbor and generated from the RNA compete assay
and calculated the minimum Kullback-Leibler divergence between the two mo-
tifs. We plotted the log DKL - min log(DKL) of the nearest neighbor motifs (x-
axis) against the affinity regression motifs (y-axis) to compare the divergences
from the ground truth motifs (Fig. 4.3). We plotted the probability density (Fig.
4.4) and cumulative distribution (Fig. 4.5) functions of log DKL - min log(DKL)
for both affinity regression motifs and nearest neighbor motifs and see that the
affinity regression motifs have a distribution of Kullback-Leibler divergences
which is shifted to the left of the distribution for the nearest neighbor. In 10-fold
crossvalidation on the full data set of RBPs, we found that the AR-predicted mo-
tifs were significantly closer to ground truth motifs (generated by the same motif
algorithm on the experimental Z-scores) than nearest neighbor motifs (Wilcoxon
signed rank test, p < 7.66e-10).
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Figure 4.2: AR-derived motif prediction for RBPs. AR motifs are gener-
ated by running PWM-Align-Z on the top 100 7-mers as pre-
dicted for held-out RBPs using the Z-score affinity regression
model (10-fold cross-validation). In the inner circle, we show
the ground truth motif obtained from the experimental data Y ,
the middle circle shows motif obtained by AR, and the outer
circle shows the motif obtained by NN. Plotted are predictions
for both RRM and KH-I domains. The RRM motifs are well
predicted by both AR and NN; KH family proteins are less well
represented in the data set, and KH-I motifs are harder to pre-
dict for both methods.
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Figure 4.3: RBP motif accuracy. Predicted motifs were assessed for qual-
ity relative to ground truth by DKL, computed by sliding the
predicted PWM over the ground truth PWM and reporting the
minimum DKL. The NN (y-axis) and AR (x-axis) log(DKL) scores
are plotted after subtracting the minimum log(DKL) for the data
set. Motifs falling in the gray area satisfy a quality threshold
equal to the median divergence between motifs from experi-
mental replicates. AR-predicted motifs are significantly more
accurate than NN motifs (p < 7.66 × 10-10, Wilcoxon signed
rank test).
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Figure 4.4: Probability density function of log(DKL) for affinity regres-
sion and nearest neighbor. Probability density function of
held-out log(DKL) for AR and NN.
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Figure 4.5: Cumulative distribution function of log(DKL) for affinity re-
gression and nearest neighbor. Cumulative distribution func-
tion of held-out log(DKL) for AR and NN.
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CHAPTER 5
CONCLUSION
5.1 Conclusion and future directions
5.1.1 Introduction
In recent years researcher have found evidence of microenvironment-mediated
drug resistance to targeted cancer therapies [2, 9, 38, 45, 47], recently generating
two high throughput data sets studying stromal mediated drug resistance in
co-cultures [41, 48]. In my dissertation, I developed a new supervised learning
strategy for modeling cancer-stromal cell paracrine signaling from anti-cancer
drug sensitivity co-culture experiments. In the co-culture analysis, our mod-
eling was limited by the size of our data set. In this context, our modeling
provides a proof-of-principle analysis that could be applied to larger co-culture
data sets in the future and that could yield novel insights into interactions me-
diating drug resistance.
In this dissertation we applied supervised learning methods with pairwise
features including multi-task affinity regression and multi-task pairwise SVM,
to model biological interactions in two different contexts. In one context we
modeled microenvironment-mediated drug resistance to targeted cancer thera-
pies. In a second context, we modeled the binding affinity of nucleic acid and
proteins in PBM and RNAcompete experiments. This dissertation is intended to
serve as both (1) a point of reference for experimental biologists looking to use
practical computational methods to model tumor-stromal interactions in stud-
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ies of the molecular mechanisms mediating innate drug resistance and (2) more
generally a starting point for computational biologists interested in modeling
biological interaction data.
5.1.2 Stromal-mediated drug resistance
In this dissertation, I explored modeling microenvironment-mediated drug re-
sistance as the interaction between molecular components of cancer cells and
stromal cells [30]. Using an expression-based pathway feature representation
for cancer cells and a cytokine expression level representation for stromal cells,
I trained affinity regression models to predict stromal-mediated rescue scores of
cancer cells for each drug; I employed a multi-task strategy to share information
across models for different dosages of the same drug or different drugs of the
same class. As a bilinear regression model, affinity regression allows us to de-
fine feature space mappings using the trained model. The mappings identified
the cytokines that are most strongly associated with resistance/sensitivity for
each cancer cell line, as well as the cancer cell pathways that appear to medi-
ate resistance/sensitivity for each stromal cell line. Through an empirical null
model, I assigned statistical significance to these key predicted features. This
analysis recovered the finding that stromal-derived HGF mediates resistance to
BRAF inhibitors in melanoma cell lines. Moreover, our affinity regression analy-
sis predicted that HGF would mediate resistance to EGFR inhibitors in lung can-
cer cell lines. Follow-up experiments with afatinib and erlonitib confirmed this
clinically relevant prediction. I also explored an alternative supervised learn-
ing method that models biological interaction data using a multi-task pairwise
SVM. I compare the performance of the SVM with affinity regression using 10-
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fold cross-validation trained on a tumor-stromal co-culture drug screen data set.
The largest limitation of our study is the small training data set size. Ideally,
we would use on the order of 100 stromal and cancer cell lines with a full matrix
of co-culture experiments as training data for each drug and dosage; in practice,
the co-culture matrix consisted of 10-20 cancer cell lines by a similar number
of stromal cell lines, and a different matrix of co-cultures was assayed for each
drug. While our multi-task strategy helps improve model accuracy in this low
training data setting, it cannot fully address the fact that we are not adequately
sampling the space of cancer-stromal interactions. The current work provides a
proof-of-principle that supervised learning can derive novel findings from co-
culture drug sensitivity data sets, providing a path forward for future larger-
scale studies.
Another limitation of our study was the fact that we were using available
static data sets from the cancer and stromal cell lines in monoculture. On the
cancer side, we had gene expression data collected from cancer cell lines in
monoculture. On the stromal side we had cytokine expression collected from
stromal cell secretion in monoculture. If we had gene expression data collected
from cancer cell lines in co-culture experiments and if we had stromal cell cy-
tokine secretion from co-culture data, it would give more dynamic rather than
static sources of information for our modeling. This could potentially yield
novel insights into the paracrine signaling mechanisms between tumor and stro-
mal cells.
In recent years, two high-throughput screens have produced a significant
amount of data that has added to our understanding of resistance to molec-
ularly targeted therapies [41, 48]. The identification of HGF as a mediator of
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vemurafenib resistance has had translational impact. Both groups suggest clin-
ical investigation of the concurrent treatment of BRAF inhibitors with the FDA-
approved MET inhibitor crizotinib. The work in this dissertation to understand
drug resistance against targeted therapies mediated by the tumor microenvi-
ronment could potentially lead to combination drug therapies targeting both
the tumor and the microenvironment. Therapies that target oncogenic signaling
pathways of cancer cells while manipulating secreted factors of the microenvi-
ronment may provide a new treatment option to abrogate cancer resistance in
clinical settings.
The genomics field has become increasingly data rich due to the availabil-
ity of high-throughput technologies such as next-generation sequencing and
microarray profiling. In our analysis we made use of the mRNA expression
signature representation of cancer cell lines due to the availability of large cell
line profiling studies. Looking forward, it is imaginable that high-throughput
techniques such as RNA-Seq, ChIP-Seq, miRNA chips, lncRNA profiling, and
next-generation sequencing can produce a large pool of data that can be used to
identify predictive biomarkers to personalize patient treatment. For our analy-
sis, phosphoproteomic data might be more directly relevant as a representation
of active signaling pathways in cancer cells. Data resources based on technolo-
gies like reverse-phase protein array [25] and mass spectrometry [31] are grow-
ing. However, the overlap of available proteomics data sets with the cancer
cell lines in our study remains limited. Perhaps once new data sources become
available in the future, they could be leveraged using the supervised learning
methods proposed in this dissertation.
89
5.1.3 Learning families of transcription factors and RNA bind-
ing proteins from PBM and RNAcompete data
In another context, affinity regression was used to model nucleic acid-protein
binding in PBM and RNAcompete experiments. In this context, we used affin-
ity regression to learn the DNA or RNA recognition code for families of TFs
or RBPs directly from the protein sequence and probe-level binding data from
PBM or RNAcompete experiments. Affinity regression trains on PBM or RNA-
compete experiments to learn an interaction model between proteins and nu-
cleic acids. Learning from PBM or RNAcompete data for diverse TFs and RBPs,
the affinity regression model can predict the binding affinities of held-out pro-
teins and identify key DNA/RNA-binding residues. Affinity regression recov-
ers predicted Z-scores with high correlation with experimental Z-scores and
with high overlap between the top 8-mers from the predicted and experimen-
tal Z-scores. Affinity regression recovered motifs with higher motif accuracy or
smaller Kullback-Leibler divergence to ground truth motifs than nearest neigh-
bor motifs.
Future directions for learning families of transcription factors and RNA bind-
ing proteins from PBM and RNAcompete data
Our affinity regression model can be extended to predict binding affinity of new
proteins in future PBM and RNAcompete experiments. In this study we pre-
dicted the binding affinity of homeodomain proteins. The affinity regression
method can also be applied to other transcription factor families whose binding
affinities to DNA probes were measured in PBM experiments [34]. Other tran-
90
scription factor families whose binding affinity could be modeled with affinity
regression include: C2H2 ZF, bZIP, Zinc cluster, Myb/SANT, bHLH, Nuclear
receptor, AP2, GATA, Sox, and Forkhead transcription factor families. It would
be interesting to look at the predicted DNA binding residues of the transcription
factor families other than homeodomain and compare their binding residues to
the residues of the homeodomain family.
5.1.4 Conclusion
In my dissertation, I applied two supervised learning methods: multi-task affin-
ity regression and multi-task pairwise SVM to cell co-culture systems with
quantitative phenotypes. Affinity regression was also used to learn the binding
recognition code for families of TFs and RBPs from PBM/RNAcompete data.
The DNA recognition code for a family of TFs or RBPs was learned from PBM
or RNAcompete data. More broadly, the affinity regression can be used to train a
bilinear interaction model for any macromolecular or cellular interactions where
interactors are described by features and where a high-throughput affinity read-
out is available and these supervised learning methods may be used as a general
strategy to model and interpret biological interaction data.
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